source
- The future of RAS inhibitorsRevolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the re…Fierce Biotech · 6h ago↗ source
- FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerThe FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.Fierce Biotech · 6h ago↗ source
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…